TY - JOUR
T1 - Awareness and knowledge of HPV and HPV vaccination among adults ages 27–45 years
AU - Thompson, Erika L.
AU - Wheldon, Christopher W.
AU - Rosen, Brittany L.
AU - Maness, Sarah B.
AU - Kasting, Monica L.
AU - Massey, Philip M.
N1 - Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/3/30
Y1 - 2020/3/30
N2 - Objective: Recent guidelines indicate adults 27–45 years old can receive the human papillomavirus (HPV) vaccine based on a shared-decision with their healthcare provider. With this expansion in recommendations, there is a need to examine the awareness and knowledge of HPV and HPV vaccination among this age group for cancer prevention. Methods: HINTS-5 Cycle-2 is a national survey of US adults, and was restricted to a complete case analysis of adults ages 27–45 years (N = 725). Sociodemographic, healthcare, and health information correlates were assessed for the outcomes of HPV awareness, HPV vaccine awareness, knowledge of HPV and cervical cancer, and knowledge of HPV and non-cervical cancers. Survey-weighted logistic regression models were conducted. Results: Most respondents were aware of HPV (72.9%) and HPV vaccination (67.1%). Respondents were more likely to be aware of HPV and HPV vaccination if they were female, had a higher level of education, and had previous cancer information seeking behaviors. Although there was widespread knowledge of HPV as a cause of cervical cancer (79.6%), knowledge of HPV as a cause of non-cervical cancers was reported by a minority of respondents (36.1%). College education was positively associated with cervical cancer knowledge (aOR = 4.62; 95%CI: 1.81–11.78); however, no significant correlates were identified for non-cervical HPV associated cancer knowledge. Conclusion: While more than half of adults ages 27–45 years are aware of HPV and HPV vaccination, there are opportunities to improve awareness and knowledge, particularly related to non-cervical cancers, as these are critical first steps toward shared decision-making for HPV vaccination in mid-adulthood.
AB - Objective: Recent guidelines indicate adults 27–45 years old can receive the human papillomavirus (HPV) vaccine based on a shared-decision with their healthcare provider. With this expansion in recommendations, there is a need to examine the awareness and knowledge of HPV and HPV vaccination among this age group for cancer prevention. Methods: HINTS-5 Cycle-2 is a national survey of US adults, and was restricted to a complete case analysis of adults ages 27–45 years (N = 725). Sociodemographic, healthcare, and health information correlates were assessed for the outcomes of HPV awareness, HPV vaccine awareness, knowledge of HPV and cervical cancer, and knowledge of HPV and non-cervical cancers. Survey-weighted logistic regression models were conducted. Results: Most respondents were aware of HPV (72.9%) and HPV vaccination (67.1%). Respondents were more likely to be aware of HPV and HPV vaccination if they were female, had a higher level of education, and had previous cancer information seeking behaviors. Although there was widespread knowledge of HPV as a cause of cervical cancer (79.6%), knowledge of HPV as a cause of non-cervical cancers was reported by a minority of respondents (36.1%). College education was positively associated with cervical cancer knowledge (aOR = 4.62; 95%CI: 1.81–11.78); however, no significant correlates were identified for non-cervical HPV associated cancer knowledge. Conclusion: While more than half of adults ages 27–45 years are aware of HPV and HPV vaccination, there are opportunities to improve awareness and knowledge, particularly related to non-cervical cancers, as these are critical first steps toward shared decision-making for HPV vaccination in mid-adulthood.
KW - Adults
KW - Awareness
KW - HPV
KW - Knowledge
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85078860863&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000525317500009&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1016/j.vaccine.2020.01.053
DO - 10.1016/j.vaccine.2020.01.053
M3 - Article
C2 - 32029321
SN - 0264-410X
VL - 38
SP - 3143
EP - 3148
JO - Vaccine
JF - Vaccine
IS - 15
ER -